midodrine has been researched along with Liver Cirrhosis in 41 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Seventy-five patients with cirrhosis and refractory ascites were randomized to receive albumin infusion, oral midodrine for 2 days, or oral midodrine for 30 days after therapeutic large volume paracentesis (LVP)." | 9.30 | Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. ( Eletreby, R; Elkady, MA; Hamza, I; Ismail, A; Soliman, ZA; Yosry, A, 2019) |
| "Fifty cirrhotic patients with refractory or recurrent ascites were randomised to receive midodrine (n=13), tolvaptan (n=12) or both (n=13) plus standard medical therapy (SMT) or SMT alone (n=12)." | 9.24 | Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. ( Bhalla, A; Rai, N; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R, 2017) |
| "Adding rifaximin and midodrine to DT enhanced diuresis in refractory ascites with improved systemic, renal hemodynamics and short-term survival." | 9.22 | Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. ( Hanafy, AS; Hassaneen, AM, 2016) |
| "Midodrine appeared to be effective in lowering body weights and abdominal girths of non azotemic cirrhotic patients with tense ascites." | 9.19 | Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. ( Al-Garem, N; Ali, A; Amin, M; Farid, S; Kassem, M, 2014) |
| " Midodrine and a combination of midodrine and clonidine plus SMT were superior to SMT alone in the control of ascites (P=0." | 9.17 | Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Ghai, A; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R, 2013) |
| "Forty cirrhotic patients with refractory or recurrent ascites were prospectively studied after long term administration of midodrine plus standard medical therapy (n=20) or standard medical therapy alone (n=20) in a randomized controlled trial at a tertiary centre." | 9.16 | Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Dhungana, SP; Gupta, PK; Nain, CK; Sharma, N; Singh, B; Singh, V; Vijayverghia, R, 2012) |
| "Oral midodrine does not increase the natriuretic response to furosemide in non-azotemic cirrhotic patients with ascites." | 9.14 | The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. ( Chalasani, N; Hamman, M; Jones, D; Kahi, C; Kwo, PY; Misra, VL; Vuppalanchi, R, 2010) |
| "Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap." | 8.02 | Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021) |
| "Midodrine is an α-agonist prodrug of desglymidodrine used for the management of hypotension, and can also be used for hepatorenal syndrome and cirrhotic patients with tense ascites." | 7.83 | Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers. ( Al-Garem, N; Al-Ghobashy, M; Ali, A; Amin, M; Farid, S; Kassem, M, 2016) |
| "Terlipressin is an analog of the natural hormone arginine-vasopressin." | 6.44 | Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. ( Bendtsen, F; Borup, T; Krag, A; Møller, S, 2008) |
| "Seventy-five patients with cirrhosis and refractory ascites were randomized to receive albumin infusion, oral midodrine for 2 days, or oral midodrine for 30 days after therapeutic large volume paracentesis (LVP)." | 5.30 | Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. ( Eletreby, R; Elkady, MA; Hamza, I; Ismail, A; Soliman, ZA; Yosry, A, 2019) |
| "Fifty cirrhotic patients with refractory or recurrent ascites were randomised to receive midodrine (n=13), tolvaptan (n=12) or both (n=13) plus standard medical therapy (SMT) or SMT alone (n=12)." | 5.24 | Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. ( Bhalla, A; Rai, N; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R, 2017) |
| "Adding rifaximin and midodrine to DT enhanced diuresis in refractory ascites with improved systemic, renal hemodynamics and short-term survival." | 5.22 | Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. ( Hanafy, AS; Hassaneen, AM, 2016) |
| "Fifty patients with cirrhosis and tense refractory ascites were randomly assigned to be treated with either midodrine (n=25) (12." | 5.19 | Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study. ( ElBaz, AA; Hamdy, H; Hassan, A; Hassanin, O, 2014) |
| "Midodrine appeared to be effective in lowering body weights and abdominal girths of non azotemic cirrhotic patients with tense ascites." | 5.19 | Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial. ( Al-Garem, N; Ali, A; Amin, M; Farid, S; Kassem, M, 2014) |
| " Midodrine and a combination of midodrine and clonidine plus SMT were superior to SMT alone in the control of ascites (P=0." | 5.17 | Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Ghai, A; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R, 2013) |
| "Forty cirrhotic patients with refractory or recurrent ascites were prospectively studied after long term administration of midodrine plus standard medical therapy (n=20) or standard medical therapy alone (n=20) in a randomized controlled trial at a tertiary centre." | 5.16 | Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. ( Bhalla, A; Dhungana, SP; Gupta, PK; Nain, CK; Sharma, N; Singh, B; Singh, V; Vijayverghia, R, 2012) |
| "Oral midodrine does not increase the natriuretic response to furosemide in non-azotemic cirrhotic patients with ascites." | 5.14 | The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. ( Chalasani, N; Hamman, M; Jones, D; Kahi, C; Kwo, PY; Misra, VL; Vuppalanchi, R, 2010) |
| "Twenty-four patients with cirrhosis and ascites were randomly assigned to be treated with either midodrine (n=11) (12." | 5.13 | Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. ( Appenrodt, B; Grünhage, F; Heller, J; Lammert, F; Rabe, C; Sauerbruch, T; Schepke, M; Trebicka, J; Wolf, A, 2008) |
| "To review studies evaluating the use of midodrine and octreotide in hemodynamic complications of cirrhosis, including ascites and hepatorenal syndrome." | 4.85 | Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. ( Karwa, R; Woodis, CB, 2009) |
| "Midodrine along with albumin infusion, is helpful in the secondary prophylaxis of HRS-AKI and reduces the number of ascites tap." | 4.02 | Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. ( Arora, A; Bansal, N; Kumar, A; Puri, P; Sharma, P; ShriHari, AA; Singla, V, 2021) |
| "Midodrine is an α-agonist prodrug of desglymidodrine used for the management of hypotension, and can also be used for hepatorenal syndrome and cirrhotic patients with tense ascites." | 3.83 | Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers. ( Al-Garem, N; Al-Ghobashy, M; Ali, A; Amin, M; Farid, S; Kassem, M, 2016) |
| "Treatment with midodrine and albumin was associated with a slight but significant decrease in plasma renin activity and aldosterone compared to placebo (renin -4." | 2.87 | Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. ( Ariza, X; Castellote, J; Colmenero, J; Córdoba, J; de Prada, G; Fabrellas, N; Garcia-Martínez, R; Ginès, P; Graupera, I; Guevara, M; Huelin, P; Lopez Benaiges, E; Manríquez, M; Márquez, F; Martín-Llahí, M; Moreira, R; Navasa, M; Nazar, A; Pavesi, M; Pose, E; Simón-Talero, M; Solà, E; Solé, C; Suñé, P; Torrens, M; Vargas, V; Ventura, M; Xiol, X, 2018) |
| "Midodrine therapy was cheaper than albumin therapy." | 2.73 | Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. ( Bhalla, A; Chawla, D; Dheerendra, PC; Mahi, SK; Nain, CK; Sharma, N; Singh, B; Singh, V, 2008) |
| "Midodrine may have treatment effects on cirrhotic ascites." | 2.53 | Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis. ( Cheng, G; Guo, TT; Liu, ZX; Ren, Y; Song, Y; Yang, Y, 2016) |
| "Liver cirrhosis is a major cause of morbidity and mortality worldwide, mainly due to complications of portal hypertension." | 2.53 | Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. ( Bertino, G; Crisafulli, E; Demma, S; Koukias, N; Privitera, G; Purrello, F; Spadaro, L; Tsochatzis, EA, 2016) |
| "Terlipressin is an analog of the natural hormone arginine-vasopressin." | 2.44 | Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. ( Bendtsen, F; Borup, T; Krag, A; Møller, S, 2008) |
| "Midodrine (MD) is a prodrug that is converted after oral administration to Desglymidodrine (DMD)." | 1.42 | Development and validation of LC-MS/MS assay for the determination of the prodrug Midodrine and its active metabolite Desglymidodrine in plasma of ascitic patients: Application to individualized therapy and comparative pharmacokinetics. ( Al-Ghobashy, MA; Ali, AA; Farid, SF; Kassem, MA, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.44) | 18.2507 |
| 2000's | 11 (26.83) | 29.6817 |
| 2010's | 24 (58.54) | 24.3611 |
| 2020's | 5 (12.20) | 2.80 |
| Authors | Studies |
|---|---|
| Flamm, SL | 1 |
| Wong, F | 3 |
| Ahn, J | 1 |
| Kamath, PS | 1 |
| Marigliano, B | 1 |
| Internullo, M | 1 |
| Scuro, L | 1 |
| Tavanti, A | 1 |
| Del Vecchio, LR | 1 |
| Schito, MB | 1 |
| Colombo, GM | 1 |
| Guglielmelli, E | 1 |
| Hiruy, A | 1 |
| Nelson, J | 1 |
| Zori, A | 1 |
| Morelli, G | 1 |
| Cabrera, R | 1 |
| Kamel, A | 1 |
| Kulkarni, AV | 1 |
| Sharma, M | 1 |
| Kumar, P | 1 |
| Gupta, R | 1 |
| Rao, PN | 1 |
| Sharma, P | 1 |
| Puri, P | 1 |
| Bansal, N | 1 |
| Singla, V | 1 |
| Kumar, A | 1 |
| ShriHari, AA | 1 |
| Arora, A | 1 |
| Stine, JG | 1 |
| Wang, J | 1 |
| Cornella, SL | 1 |
| Behm, BW | 1 |
| Henry, Z | 1 |
| Shah, NL | 1 |
| Caldwell, SH | 1 |
| Northup, PG | 1 |
| Solà, E | 2 |
| Solé, C | 2 |
| Simón-Talero, M | 1 |
| Martín-Llahí, M | 1 |
| Castellote, J | 1 |
| Garcia-Martínez, R | 1 |
| Moreira, R | 1 |
| Torrens, M | 1 |
| Márquez, F | 1 |
| Fabrellas, N | 1 |
| de Prada, G | 1 |
| Huelin, P | 1 |
| Lopez Benaiges, E | 1 |
| Ventura, M | 1 |
| Manríquez, M | 1 |
| Nazar, A | 1 |
| Ariza, X | 1 |
| Suñé, P | 1 |
| Graupera, I | 1 |
| Pose, E | 1 |
| Colmenero, J | 1 |
| Pavesi, M | 1 |
| Guevara, M | 1 |
| Navasa, M | 1 |
| Xiol, X | 1 |
| Córdoba, J | 1 |
| Vargas, V | 1 |
| Ginès, P | 3 |
| Yosry, A | 1 |
| Soliman, ZA | 1 |
| Eletreby, R | 1 |
| Hamza, I | 1 |
| Ismail, A | 1 |
| Elkady, MA | 1 |
| Singh, V | 5 |
| Singh, A | 3 |
| Agarwal, R | 1 |
| Singh, B | 4 |
| Vijayvergiya, R | 2 |
| Sharma, N | 4 |
| Ghai, A | 1 |
| Bhalla, A | 4 |
| Hsu, SJ | 1 |
| Huang, HC | 1 |
| Hamdy, H | 1 |
| ElBaz, AA | 1 |
| Hassan, A | 1 |
| Hassanin, O | 1 |
| Sourianarayanane, A | 1 |
| Raina, R | 1 |
| Garg, G | 1 |
| McCullough, AJ | 1 |
| O'Shea, RS | 1 |
| Ali, A | 2 |
| Farid, S | 2 |
| Amin, M | 2 |
| Kassem, M | 2 |
| Al-Garem, N | 2 |
| Ali, AA | 1 |
| Al-Ghobashy, MA | 1 |
| Farid, SF | 1 |
| Kassem, MA | 1 |
| Velez, JC | 1 |
| Kadian, M | 1 |
| Taburyanskaya, M | 1 |
| Bohm, NM | 1 |
| Delay, TA | 1 |
| Karakala, N | 1 |
| Rockey, DC | 1 |
| Nietert, PJ | 1 |
| Goodwin, AJ | 1 |
| Whelan, TP | 1 |
| Al-Ghobashy, M | 1 |
| Guo, TT | 1 |
| Yang, Y | 1 |
| Song, Y | 1 |
| Ren, Y | 1 |
| Liu, ZX | 1 |
| Cheng, G | 1 |
| Salman, TA | 1 |
| Edrees, AM | 1 |
| El-Said, HH | 1 |
| El-Abd, OL | 1 |
| El-Azab, GI | 1 |
| Bertino, G | 1 |
| Privitera, G | 1 |
| Purrello, F | 1 |
| Demma, S | 1 |
| Crisafulli, E | 1 |
| Spadaro, L | 1 |
| Koukias, N | 1 |
| Tsochatzis, EA | 1 |
| Rai, N | 1 |
| Hanafy, AS | 1 |
| Hassaneen, AM | 1 |
| Dong, T | 1 |
| Aronsohn, A | 1 |
| Gautham Reddy, K | 1 |
| Te, HS | 1 |
| Dheerendra, PC | 1 |
| Nain, CK | 2 |
| Chawla, D | 1 |
| Mahi, SK | 1 |
| Kalambokis, GN | 1 |
| Tsianos, EV | 5 |
| Krag, A | 1 |
| Borup, T | 1 |
| Møller, S | 1 |
| Bendtsen, F | 1 |
| Karwa, R | 1 |
| Woodis, CB | 1 |
| Carl, DE | 1 |
| Sanyal, A | 1 |
| Misra, VL | 1 |
| Vuppalanchi, R | 1 |
| Jones, D | 1 |
| Hamman, M | 1 |
| Kwo, PY | 1 |
| Kahi, C | 1 |
| Chalasani, N | 1 |
| Kalambokis, G | 4 |
| Dhungana, SP | 1 |
| Vijayverghia, R | 1 |
| Gupta, PK | 1 |
| Olivera-Martinez, M | 1 |
| Martinez, MO | 1 |
| Sayles, H | 1 |
| Vivekanandan, R | 1 |
| D' Souza, S | 1 |
| Florescu, MC | 1 |
| Pantea, L | 1 |
| Sniderman, K | 1 |
| Fotopoulos, A | 2 |
| Economou, M | 2 |
| Pappas, K | 1 |
| Appenrodt, B | 1 |
| Wolf, A | 1 |
| Grünhage, F | 1 |
| Trebicka, J | 1 |
| Schepke, M | 1 |
| Rabe, C | 1 |
| Lammert, F | 1 |
| Sauerbruch, T | 1 |
| Heller, J | 1 |
| Angeli, P | 1 |
| Volpin, R | 1 |
| Piovan, D | 1 |
| Bortoluzzi, A | 1 |
| Craighero, R | 1 |
| Bottaro, S | 1 |
| Finucci, GF | 1 |
| Casiglia, E | 1 |
| Sticca, A | 1 |
| De Toni, R | 1 |
| Pavan, L | 1 |
| Gatta, A | 1 |
| Ortega, R | 1 |
| Calahorra, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation[NCT00839358] | Phase 4 | 199 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Egyptian Cirrhotic Patients With Ascites[NCT04785755] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-30 | Completed | ||
| Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites[NCT02173288] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children: a Pilot Study[NCT04043858] | 20 participants (Anticipated) | Interventional | 2020-06-05 | Recruiting | |||
| Rifaximin Prophylaxis Against Recurrence of Spontaneous Bacterial Peritonitis and Occurrence of Hepatorenal Syndrome in Decompensated Cirrhotic Egyptian Patients[NCT05621005] | Phase 2 | 104 participants (Actual) | Interventional | 2019-03-01 | Completed | ||
| Vasoconstrictors as Alternatives to Albumin After Large Volume Paracentesis in Cirrhosis[NCT00108355] | Phase 4 | 29 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy for the Control of Acute Variceal Bleeding in Patients With Liver Cirrhosis at a Tertiary Center in Mexico[NCT05331768] | 109 participants (Actual) | Interventional | 2021-01-01 | Completed | |||
| Efficacy of Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin. A Multi-center Randomized Controlled Study[NCT00986817] | Phase 3 | 82 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Defined as an increase in Plasma Renin Activity (PRA) by >50% from baseline to a level > 4 ng/mL/h at post-paracentesis day (NCT00108355)
Timeframe: 6 days after paracentesis
| Intervention | participants (Number) |
|---|---|
| Albumin (Control Group) | 2 |
| Vasoconstrictor (Treatment Group) | 2 |
Comparison between Albumin (Control group) and Vasoconstrictor (Treatment group) (NCT00108355)
Timeframe: Variable depending on the patient, average 10 days
| Intervention | days (Median) |
|---|---|
| Albumin (Control Group) | 10 |
| Vasoconstrictor (Treatment Group) | 8 |
9 reviews available for midodrine and Liver Cirrhosis
| Article | Year |
|---|---|
AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
Topics: Acute Kidney Injury; Albumins; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Creat | 2022 |
Management of ascites in patients with liver cirrhosis: recent evidence and controversies.
Topics: Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodrine; Portasystemic Shunt, T | 2013 |
Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis.
Topics: Bias; Data Interpretation, Statistical; Humans; Liver Cirrhosis; Midodrine; Sensitivity and Specific | 2016 |
Diagnosing and treating renal disease in cirrhotic patients.
Topics: Creatinine; Glomerular Filtration Rate; Humans; Kidney Diseases; Liver Cirrhosis; Liver Transplantat | 2016 |
Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.
Topics: Acute Kidney Injury; Adrenal Insufficiency; Ascites; Creatinine; Evidence-Based Medicine; Hepatorena | 2016 |
Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Hepatorenal Syndrome; Hum | 2008 |
Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Topics: Ascites; Hemodynamics; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Octreotide; Treatme | 2009 |
The management of hepatorenal syndrome.
Topics: Albumins; Drug Therapy, Combination; Evidence-Based Medicine; Hepatorenal Syndrome; Humans; Liver Ci | 2009 |
[Vasoconstrictors in the treatment of hepatorenal syndrome].
Topics: Adrenergic alpha-Agonists; Albumins; Drug Evaluation; Drug Therapy, Combination; Hepatorenal Syndrom | 2002 |
15 trials available for midodrine and Liver Cirrhosis
| Article | Year |
|---|---|
Treatment of Type-1 Hepatorenal Syndrome with Pentoxifylline: A Randomized Placebo Controlled Clinical Trial.
Topics: Aged; Albumins; Drug Therapy, Combination; Female; Hepatorenal Syndrome; Hospital Mortality; Humans; | 2018 |
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
Topics: Adult; Aged; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Follow-Up Studies; Humans; | 2018 |
Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study.
Topics: Administration, Oral; Adrenergic alpha-1 Receptor Agonists; Adult; Albumins; Ascites; Cost-Benefit A | 2019 |
Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-2 Receptor Agonists; Adult; Aged; Ascites; Cl | 2013 |
Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study.
Topics: Albumins; Aldosterone; Ascites; Creatinine; Female; Humans; Hypovolemia; Liver Cirrhosis; Male; Midd | 2014 |
Clinical study on the therapeutic role of midodrine in non azotemic cirrhotic patients with tense ascites: a double-blind, placebo-controlled, randomized trial.
Topics: Adrenergic alpha-1 Receptor Agonists; Aged; Ascites; Blood Flow Velocity; Double-Blind Method; Drain | 2014 |
Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis.
Topics: Adult; Bacterial Infections; Drug Therapy, Combination; Female; Hemodynamics; Hepatorenal Syndrome; | 2016 |
Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study.
Topics: Adult; Ascites; Benzazepines; Drug Therapy, Combination; Female; Humans; India; Liver Cirrhosis; Mal | 2017 |
Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival.
Topics: Aldosterone; Anti-Infective Agents; Ascites; Blood Pressure; Body Weight; Diuretics; Drug Therapy, C | 2016 |
Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.
Topics: Adult; Ascites; Female; Humans; Hypovolemia; Liver Cirrhosis; Male; Middle Aged; Midodrine; Paracent | 2008 |
The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites.
Topics: Administration, Oral; Ascites; Creatinine; Cross-Over Studies; Diuretics; Double-Blind Method; Femal | 2010 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study.
Topics: Adrenergic alpha-1 Receptor Agonists; Adult; Ascites; Female; Hemodynamics; Humans; Kidney; Liver Ci | 2012 |
Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Blood Volume; Creatinine; Drug Therapy, C | 2004 |
Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.
Topics: Adrenergic alpha-Agonists; Cardiovascular System; Drug Administration Schedule; Female; Glomerular F | 2007 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.
Topics: Adrenergic alpha-Agonists; Albumins; Aldosterone; Ascites; Double-Blind Method; Female; Humans; Hypo | 2008 |
17 other studies available for midodrine and Liver Cirrhosis
| Article | Year |
|---|---|
Midodrine and albumin as a possible "winning pair" in managing paracentesis-induced circulatory dysfunction: a clinical case report.
Topics: Albumins; Ascites; Diuretics; Female; Heart Failure; Humans; Liver Cirrhosis; Middle Aged; Midodrine | 2022 |
Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.
Topics: Albumins; Drug Therapy, Combination; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Octre | 2021 |
Letter to the Editor: Midodrine for Hepatic Hydrothorax.
Topics: Humans; Hydrothorax; Liver Cirrhosis; Midodrine | 2021 |
Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites.
Topics: Acute Kidney Injury; Albumins; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Midodrine; Pi | 2021 |
Midodrine and albumin in decompensated cirrhosis: Down but not out….
Topics: Albumins; Humans; Liver Cirrhosis; Liver Transplantation; Midodrine | 2019 |
Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out…".
Topics: Albumins; Humans; Liver Cirrhosis; Liver Transplantation; Midodrine | 2019 |
Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.
Topics: Aged; Albumins; Female; Gastrointestinal Agents; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Live | 2014 |
Development and validation of LC-MS/MS assay for the determination of the prodrug Midodrine and its active metabolite Desglymidodrine in plasma of ascitic patients: Application to individualized therapy and comparative pharmacokinetics.
Topics: Adrenergic alpha-1 Receptor Agonists; Ascites; Chromatography, High Pressure Liquid; Drug Monitoring | 2015 |
Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.
Topics: Acute Kidney Injury; Aged; Arterial Pressure; Creatinine; End Stage Liver Disease; Female; Hepatoren | 2015 |
Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers.
Topics: Adrenergic alpha-Agonists; Adult; Ascites; Case-Control Studies; Female; Humans; Liver Cirrhosis; Ma | 2016 |
Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis.
Topics: Acute Kidney Injury; Aged; Anti-Infective Agents; Case-Control Studies; End Stage Liver Disease; Fem | 2016 |
Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome.
Topics: Adrenergic alpha-Agonists; Ascites; Hepatorenal Syndrome; Humans; Liver Cirrhosis; Lypressin; Midodr | 2008 |
Midodrine and furosemide-induced natriuresis in cirrhotics with ascites.
Topics: Ascites; Furosemide; Humans; Liver Cirrhosis; Midodrine; Natriuresis | 2011 |
Hepatorenal syndrome: are we missing some prognostic factors?
Topics: Albumins; Alcoholism; Autoimmune Diseases; Creatinine; End Stage Liver Disease; Female; Hepatitis C; | 2012 |
Beneficial haemodynamic and renal sodium handling effects of combined midodrine and octreotide treatment in a cirrhotic patient with large hepatic hydrothorax and mild ascites.
Topics: Adrenergic alpha-Agonists; Aged; Ascites; Drug Therapy, Combination; Female; Gastrointestinal Agents | 2005 |
Treatment of hepatic hydrothorax with vasoconstrictor drugs.
Topics: Aged; Female; Humans; Hydrothorax; Liver Cirrhosis; Midodrine; Vasoconstrictor Agents | 2007 |
Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Topics: Administration, Oral; Adrenergic alpha-Agonists; Ascites; Blood Pressure; Cardiac Output; Female; Gl | 1998 |